Apr 28, 2026 01:31PM
Apr 28, 2026 07:30AM
Apr 8, 2026 08:00AM
Feb 24, 2026 07:30AM
Feb 19, 2026 05:30AM
Jan 12, 2026 07:34AM
Jan 12, 2026 07:30AM Kiniksa Pharmaceuticals Provides Corporate Update
Oct 28, 2025 07:30AM
Oct 17, 2025 08:00AM
Oct 17, 2025 08:00AM
Jul 29, 2025 07:30AM
Apr 29, 2025 07:30AM
Feb 25, 2025 07:30AM
Feb 25, 2025 07:29AM Kiniksa Pharmaceuticals Ltd. (KNSA) Announces Development of KPL-387
Feb 25, 2025 07:29AM
Jan 13, 2025 08:48AM
Jan 13, 2025 07:31AM
Jan 13, 2025 07:30AM
Oct 29, 2024 07:30AM
Jul 23, 2024 07:30AM
Jul 9, 2024 08:00AM Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
Apr 23, 2024 07:30AM
Apr 2, 2024 07:31AM
Apr 2, 2024 07:30AM
Feb 28, 2024 07:30AM
Jan 4, 2024 07:34AM
Jan 4, 2024 07:30AM
Oct 31, 2023 07:30AM Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
Jul 25, 2023 07:30AM
May 2, 2023 07:30AM
Feb 28, 2023 08:00AM
Jan 9, 2023 08:00AM
Nov 1, 2022 08:00AM
Aug 3, 2022 07:30AM
May 3, 2022 08:00AM Kiniksa Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Feb 22, 2022 08:00AM
Feb 22, 2022 07:59AM
Feb 22, 2022 07:59AM
Jan 10, 2022 08:00AM
Dec 28, 2021 06:59AM
Dec 28, 2021 06:59AM
Nov 1, 2021 08:00AM Kiniksa Pharmaceuticals Reports Third Quarter 2021 Financial Results and Recent Portfolio Execution
Aug 16, 2021 08:00AM
Aug 3, 2021 08:00AM
Jun 9, 2021 09:27AM
Jun 8, 2021 05:54PM
Jun 8, 2021 04:01PM
Jun 8, 2021 04:01PM
Jun 8, 2021 07:34AM Kiniksa (KNSA) Outlines Next Steps for the Development of Mavrilimumab
Jun 8, 2021 07:30AM

323,580 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All